NYSEMKT: VJETFlyte Aviation Inc Stock
$1.03-0.59 (-36.42%)
Updated Oct 6, 2026
VJET Price
$1.03
Fair Value Price
N/A
Market Cap
$1.48M
52 Week Low
$0.95
52 Week High
$32.00
P/E
-0.01x
P/B
0.08x
P/S
1.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.92M
Earnings
-$13.01M
Gross Margin
47.7%
Operating Margin
-686.16%
Profit Margin
-711.5%
Debt to Equity
1.12
Operating Cash Flow
-$9M
Beta
0.96
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
VJET Overview
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VJET's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important VJET news, forecast changes, insider trades & much more!
VJET News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VJET scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VJET is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VJET is good value based on its book value relative to its share price (0.08x), compared to the US Medical Devices industry average (2.98x)
P/B vs Industry Valuation
VJET is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VJET due diligence checks available for Premium users.
Valuation
VJET price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
21.7x
Market
51.93x
VJET price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.08x
Industry
2.98x
VJET is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VJET's financial health
Profit margin
Revenue
$1.0M
Net Income
-$3.3M
Profit Margin
-250.7%
VJET's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VJET's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$36.9M
Liabilities
$19.7M
Debt to equity
1.12
VJET's short-term liabilities ($13.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VJET's long-term liabilities ($6.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VJET's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VJET's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$833.0k
Financing
$3.9M
VJET's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VJET vs Medical Device Stocks
Flyte Aviation Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.